Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib

References

• Facchinetti F, Rossi G, Bria E, et al. Oncogene addiction in non-small cell lung cancer: focus on ROS1 inhibition. Cancer Treat Rev. 2017;55:83–95. doi:10.1016/j.ctrv.2017.02.01028342334
   PubMed Web of Science ®Google Scholar
• Sehgal K, Piper-Vallillo AJ, Viray H, Khan AM, Rangachari D, Costa DB. Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? Precis Cancer Med. 2020;3:17. doi:10.21037/pcm-2020-potb-0232776005
   PubMedGoogle Scholar
• Facchinetti F, Friboulet L. Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date. Lung Cancer Targets Ther. 2019;10:87–94. doi:10.2147/LCTT.S190786
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three Phase 1–2 trials. Lancet Oncol. 2020;21(2):261–270. doi:10.1016/S1470-2045(19)30690-431838015
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2019;20(12):1691–1701. doi:10.1016/S1470-2045(19)30655-231669155
   PubMed Web of Science ®Google Scholar
• Mezquita L, Swalduz A, Jovelet C, et al. Clinical relevance of an amplicon-based liquid biopsy for detecting ALK and ROS1 fusion and resistance mutations in patients with non–small-cell lung cancer. JCO Precis Oncol. 2020;4:PO.19.00281. doi:10.1200/po.19.00281
   Web of Science ®Google Scholar
• Nagasaka M, Ge Y, Sukari A, Kukreja G, Ou SHI. A user’s guide to lorlatinib. Crit Rev Oncol Hematol. 2020;151:102969. doi:10.1016/j.critrevonc.2020.10296932416346
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement_4):iv192–iv237. doi:10.1093/annonc/mdy275
   PubMed Web of Science ®Google Scholar
• Hanna NH, Robinson AG, Temin S, et al. Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol. 2021;39(9):1040–1091. doi:10.1200/JCO.20.0357033591844
   PubMed Web of Science ®Google Scholar
• Shaw AT, Riely GJ, Bang Y-J, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30(7):1121–1126. doi:10.1093/annonc/mdz13130980071
   PubMed Web of Science ®Google Scholar
• Wu YL, Yang JCH, Kim DW, et al. Phase II study of crizotinib in east asian patients with ROS1-positive advanced non–small-cell lung cancer. J Clin Oncol. 2018;36(14):1405–1411. doi:10.1200/JCO.2017.75.558729596029
   PubMed Web of Science ®Google Scholar
• Michels S, Massutí B, Schildhaus HU, et al. Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European phase II clinical trial. J Thorac Oncol. 2019;14(7):1266–1276. doi:10.1016/j.jtho.2019.03.02030978502
   PubMed Web of Science ®Google Scholar
• Landi L, Chiari R, Tiseo M, et al. Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a Phase II, prospective, multicentre, two-arms trial. Clin Cancer Res. 2019;25(24):7312–7319. doi:10.1158/1078-0432.CCR-19-099431416808
   PubMed Web of Science ®Google Scholar
• Lim SM, Kim HR, Lee JS, et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35(23):2613–2618. doi:10.1200/JCO.2016.71.370128520527
   PubMed Web of Science ®Google Scholar
• Cho BC, Drilon A, Doebele R, et al. Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). J Clin Oncol. 2019;37(suppl):abstr9011. doi:10.1200/JCO.2019.37.15_suppl.9011
   Google Scholar
• Papadopoulos KP, Borazanci E, Shaw AT, et al. U.S. Phase I first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2020;26(18):4785–4794. doi:10.1158/1078-0432.CCR-20-163032591465
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Ou SHI, et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7(4):400–409. doi:10.1158/2159-8290.CD-16-123728183697
   PubMed Web of Science ®Google Scholar
• Frost N, Christopoulos P, Kauffmann-Guerrero D, et al. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. Ther Adv Med Oncol. 2021;13:1758835920980558. doi:10.1177/175883592098055833613692
   PubMed Web of Science ®Google Scholar
• Hochmair MJ, Fabikan H, Illini O, et al. Later-line treatment with lorlatinib in ALK-and ROS1-rearrangement-positive nsclc: a retrospective, multicenter analysis. Pharmaceuticals. 2020;13(11):371. doi:10.3390/ph13110371
   Web of Science ®Google Scholar
• Peled N, Gillis R, Kilickap S, et al. GLASS: global lorlatinib for ALK(+) and ROS1(+) retrospective study: real world data of 123 NSCLC patients. Lung Cancer. 2020;148:48–54. doi:10.1016/j.lungcan.2020.07.02232799090
   PubMed Web of Science ®Google Scholar
• Zhu VW, Lin YT, Kim DW, et al. An international real-world analysis of the efficacy and safety of lorlatinib through early or expanded access programs in patients with tyrosine kinase inhibitor–refractory ALK-positive or ROS1-positive NSCLC. J Thorac Oncol. 2020;15(9):1484–1496. doi:10.1016/j.jtho.2020.04.01932360579
   PubMed Web of Science ®Google Scholar
• Lee J, Sun JM, Lee SH, et al. Efficacy and safety of lorlatinib in Korean non–small-cell lung cancer patients with ALK or ROS1 rearrangement whose disease failed to respond to a previous tyrosine kinase inhibitor. Clin Lung Cancer. 2019;20(3):215–221. doi:10.1016/j.cllc.2018.12.02030683630
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines®) for non-small cell lung cancer (version 2.2019). Available from: https://www.nccn.org/professionals/physician_gls/recently_updated.aspx. Accessed 319, 2021.
   Google Scholar
• Gainor JF, Tseng D, Yoda S, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non–small-cell lung cancer. J Clin Oncol. 2017;2017:PO.17.00063. doi:10.1200/PO.17.00063
   Google Scholar
• Patil T, Smith DE, Bunn PA, et al. The incidence of brain metastases in stage IV ROS1-rearranged non–small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717–1726. doi:10.1016/j.jtho.2018.07.00129981925
   PubMed Web of Science ®Google Scholar
• Coleman N, Yousaf N, Arkenau HT, Welsh L, Popat S. Lorlatinib salvages central nervous system–only relapse on entrectinib in ROS1-positive NSCLC. J Thorac Oncol. 2020;15(8):e142–e144. doi:10.1016/j.jtho.2019.12.11532718541
   PubMed Web of Science ®Google Scholar
• Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK Inhibitors in preclinical models. Cancer Cell. 2015;28(1):70–81. doi:10.1016/j.ccell.2015.05.01026144315
   PubMed Web of Science ®Google Scholar
• Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590–1599. doi:10.1016/S1470-2045(17)30680-029074098
   PubMed Web of Science ®Google Scholar